

# Momoko Nishikori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9178400/publications.pdf>

Version: 2024-02-01

56  
papers

958  
citations

687363

13  
h-index

454955

30  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1735  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. <i>Drugs - Real World Outcomes</i> , 2022, 9, 63-78.	1.6	5
2	An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. <i>International Journal of Hematology</i> , 2022, 115, 391-398.	1.6	6
3	Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. <i>International Journal of Hematology</i> , 2022, 115, 382.	1.6	3
4	Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. <i>International Journal of Hematology</i> , 2021, 113, 73-80.	1.6	18
5	Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. <i>Cancer Science</i> , 2021, 112, 3627-3635.	3.9	32
6	The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment. <i>Cancer Science</i> , 2021, 112, 4604-4616.	3.9	13
7	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. <i>PLoS ONE</i> , 2021, 16, e0237554.	2.5	20
8	A sporadic case of CTLA4 haploinsufficiency manifesting as Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, , .	0.8	1
9	Histologic transformation of t(11;18)-positive MALT lymphoma presented with aberrant T-cell marker expression. <i>International Journal of Hematology</i> , 2020, 111, 724-732.	1.6	3
10	Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. <i>International Journal of Hematology</i> , 2020, 112, 609-613.	1.6	3
11	Relapse of follicular lymphoma arising from a non-(14;18) clone. <i>EJHaem</i> , 2020, 1, 323-327.	1.0	0
12	Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study. <i>Cancer Science</i> , 2020, 111, 3367-3378.	3.9	11
13	Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2346-2358.	2.0	4
14	EBV-associated lymphoproliferative disorder in a patient with X-linked severe combined immunodeficiency with multiple reversions of an IL2RG mutation in T cells. <i>EJHaem</i> , 2020, 1, 581-584.	1.0	0
15	Establishment and characterization of a MALT lymphoma cell line carrying an API2-MALT1 translocation. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 517-524.	2.8	3
16	LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. <i>Blood</i> , 2020, 136, 684-697.	1.4	32
17	Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab. <i>Annals of Hematology</i> , 2020, 99, 887-889.	1.8	5
18	EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. <i>Molecular Immunology</i> , 2020, 119, 35-45.	2.2	28

#	ARTICLE	IF	CITATIONS
19	Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders. <i>Annals of Hematology</i> , 2020, 99, 1565-1573.	1.8	3
20	Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. <i>Bone Marrow Transplantation</i> , 2019, 54, 326-329.	2.4	13
21	Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group. <i>Annals of Hematology</i> , 2019, 98, 2815-2823.	1.8	11
22	Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 849-860.	2.3	11
23	Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases. <i>Bone Marrow Transplantation</i> , 2019, 54, 1710-1712.	2.4	2
24	End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W-J H S NHL01 Study. <i>Blood</i> , 2019, 134, 5245-5245.	1.4	0
25	Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2085-2095.	1.3	9
26	B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33. <i>Blood Advances</i> , 2018, 2, 2282-2295.	5.2	19
27	Mechanisms Underlying Augmented Lymphomagenesis by LUBAC; Possible Accumulation of AID-Mediated Somatic Mutations. <i>Blood</i> , 2018, 132, 775-775.	1.4	0
28	Clinical Analysis of Immunodeficiency-Associated Lymphoproliferative Disorders in a Single Institution. <i>Blood</i> , 2018, 132, 5398-5398.	1.4	0
29	Persistence of a t(11;14)-positive clone in a patient with mantle cell lymphoma for 20 years. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 477-481.	0.5	0
30	Outcome of allogeneic hematopoietic stem cell transplantation in cases of mature T/NK-cell neoplasms: a single-center retrospective analysis. <i>Annals of Hematology</i> , 2017, 96, 323-326.	1.8	4
31	Expression of Tim-1 in primary CNS lymphoma. <i>Cancer Medicine</i> , 2016, 5, 3235-3245.	2.8	20
32	Notch1-Activated B Cells Have an Immunomodulatory Function Enhancing Th2 and Treg Immune Response Via IL-33-ST2 Pathway. <i>Blood</i> , 2016, 128, 130-130.	1.4	12
33	Dose-Adjusted (DA) - EPOCH-R with High-Dose Methotrexate for Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma (CD5+ DLBCL): Interim Results from a Phase II Study. <i>Blood</i> , 2016, 128, 3029-3029.	1.4	1
34	Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. <i>International Journal of Hematology</i> , 2015, 102, 53-58.	1.6	6
35	STX 11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas. <i>Cancer Science</i> , 2015, 106, 1455-1462.	3.9	17
36	Expression of Tim-1 and Its Pathogenetic Role in Primary CNS Lymphoma. <i>Blood</i> , 2014, 124, 2961-2961.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Ki-67 Is a Strong Predictor for Central Nervous System Relapse in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2014, 124, 1660-1660.	1.4	0
38	STX11 Acts As a Novel Tumor Suppressor Gene in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2014, 124, 1615-1615.	1.4	0
39	Long-term remission in patients with plasma cell myeloma after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. <i>Journal of Hematopoietic Cell Transplantation</i> , 2013, 2, 25-31.	0.1	0
40	Deregulation of CCND1 or BCL2 in the Immature B-Cell Stage Determines the Resulting Lymphoma Histology. <i>Blood</i> , 2012, 120, 416-416.	1.4	0
41	A case of HIV-associated lymphoproliferative disease that was successfully treated with highly active antiretroviral therapy. <i>International Journal of Hematology</i> , 2010, 91, 692-698.	1.6	4
42	Idiopathic CD4 Lymphocytopenia Due to Loss of Heterozygosity of the Mutant CD2 Gene. <i>Blood</i> , 2010, 116, 2774-2774.	1.4	2
43	Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. <i>International Journal of Hematology</i> , 2009, 89, 538-545.	1.6	8
44	B7 $\alpha$ H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. <i>Cancer Science</i> , 2009, 100, 2093-2100.	3.9	122
45	Distinctive cell properties of B cells carrying the <i>BCL2</i> translocation and their potential roles in the development of lymphoma of germinal center type. <i>Cancer Science</i> , 2009, 100, 2361-2367.	3.9	6
46	PD-1/PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. <i>Blood</i> , 2008, 111, 3220-3224.	1.4	362
47	B Cells with BCL2/IGH Translocation Compose a Distinctive Cell Population That May Serve as a Reservoir of Lymphoma of Germinal Center B-Cell Type. <i>Blood</i> , 2008, 112, 2050-2050.	1.4	0
48	PD-1/PD-1-Ligand Interaction Contributes to Immunosuppressive Microenvironment of Hodgkin Lymphoma. <i>Blood</i> , 2007, 110, 379-379.	1.4	0
49	Molecular Pathogenesis of Hodgkin Lymphoma. <i>International Journal of Hematology</i> , 2006, 83, 398-403.	1.6	11
50	Reappraisal of BCL3 as a Molecular Marker of Anaplastic Large Cell Lymphoma. <i>International Journal of Hematology</i> , 2005, 82, 397-405.	1.6	13
51	Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3. <i>Cancer Science</i> , 2005, 96, 487-497.	3.9	35
52	Shared and Differential Gene Expression Profiles between Anaplastic Large Cell Lymphoma and Hodgkin Lymphoma Revealed by Supervised Clustering Analyses. <i>Blood</i> , 2004, 104, 4303-4303.	1.4	0
53	High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. <i>Blood</i> , 2003, 101, 2789-2796.	1.4	53
54	Primary Mediastinal Large B-Cell Lymphoma: A Comparative Study With Nodular Sclerosis-Type Hodgkin's Disease. <i>International Journal of Hematology</i> , 2001, 74, 178-185.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Heterogeneous Breakpoints on the Immunoglobulin Genes Are Involved in Fusion with the 5' Region of BCL2 in B-Cell Tumors. Japanese Journal of Cancer Research, 2001, 92, 933-940.	1.7	17
56	Intravascular clusters of T cells following chimeric antigen receptor T cell therapy. EJHaem, 0, , 2395.	1.0	1